Figure 1
From: RNAi-mediated knock-down of Dab and Numb attenuate Aβ levels via γ-secretase mediated APP processing
Effects of RNAi knock-down of Dab on APP processing and Aβ levels in H4-FL-APP cells. In H4-FL-APP cells, Dab siRNA treatment decreases protein levels of Dab, increases protein levels of APP-C83 and APP-C99, and decreases Aβ levels. A. APP processing in Western blot analyses. Dab immunoblotting shows reductions in protein levels of Dab in the cells treated with Dab siRNA (columns 3 and 4) as compared to control siRNA (columns 1 and 2). FL-APP immunoblotting reveals that there is no significant difference in the protein levels of FL-APP in the cells treated with control siRNA or Dab siRNA. APP-CTFs immunoblotting shows increases in protein levels of APP-C99 and APP-C83 in the cells treated with Dab siRNA (columns 3 and 4) as compared to control siRNA (columns 1 and 2). B. Protein levels of Dab assessed by quantifying Dab in the Western blot. Dab siRNA treatment (black bar) significantly decreases protein levels of Dab as compared to control siRNA treatment (white bar) (*p < 0.05), normalized to β-actin. C. APP processing assessed by quantifying ratio of APP-C99 to FL-APP in the Western blot. Dab siRNA treatment (black bar) significantly increases ratio of APP-C99 to FL-APP as compared to control siRNA treatment (white bar) (*p < 0.05), normalized to β-actin. D. APP processing assessed by quantifying ratio of APP-C83 to FL-APP in the Western blot. Dab siRNA treatment (black bar) significantly increases ratio of APP-C83 to FL-APP as compared to control siRNA treatment (white bar) (*p < 0.05), normalized to β-actin. E. Effects of RNAi knock-down of Dab on Aβ levels in H4-FL-APP cells. Dab siRNA treatment (black bar) decreases Aβ40 levels as compared to control siRNA treatment (white bar) (*p < 0.05).